Kornimate/medical-research-clean huggingface dataset:
preoperative mindfulness in musculoskeletal tumor

Conditions: Musculoskeletal Malignancy

Summary: psychosocial distress is common in patients with an oncologic diagnosis, with anxiety being present in almost 20-30% of the patients.\[1, 2, 10\] mindfulness exercises have shown to reduce this distress.\[4, 5\] recently, the implementation of a 60-second mindfulness-based intervention has shown to have momentary effects on pain, anxiety, depression and anger in orthopaedic upper extremity patients.\[9\] however, its lasting effect after the single intervention was not evaluated. nonetheless, because the intervention is not time consuming and is easy to implement it may benefit orthopaedic oncology patients in their pre-operative coping. the implementation of a 60-second mindfulness-based intervention has shown to have momentary effects on pain, anxiety, depression and anger in orthopaedic upper extremity participants. in this research study, the investigators are studying a 60-second interactive personalized acceptance-based mindfulness exercise

the aim of this study is to evaluate the effect of a preoperative 60-second interactive personalized acceptance-based mindfulness exercise (intervention) versus a brief educational pamphlet (control) on anxiety in patients undergoing curative surgery for a musculoskeletal malignancy.

Eligibility criteria:
inclusion criteria: * all adult (\>18 years) patients attending the orthopaedic oncology department outpatient clinic (dr. santiago lozano-calderon, dr. kevin raskin, dr. j. schwab) at the mgh with a histologically confirmed musculoskeletal malignancy undergoing curative surgery will be enrolled at their last preoperative visit. * patients with a musculoskeletal malignancy undergoing curative surgical treatment * histologic confirmation of malignancy prior to curative surgery * primary surgery of musculoskeletal malignancy at the massachusetts general hospital * able to give informed consent * english fluency and literacy --- english fluency is needed because the intervention (a 60-seconds video) is in english and there is no alternate version available. * age ≥18 years exclusion criteria: * significant axis i or ii psychopathology that would interfere with participation in the study * pregnant patients * metastasis at presentation

Keywords: musculoskeletal malignancy
comparison of cariostatic effect of nano-silver fluoride versus silver diamine fluoride

Conditions: Dental Caries in Children

Summary: this study will be conducted to test the cariostatic effect of nano silver fluoride in a comparison to silver diamine fluoride in a group of preschool children.

silver diamine fluoride has offered a non-invasive and easily performed method to manage dental caries in very young children.studies shows that sdf has been proven to arrest caries in cavitated lesions and to prevent caries in sound teeth as fluoride is effective in enhancing the remineralization of dental hard tissue and silver ion acts as an antibacterial agent. however, it was found that silver causes staining to the dental tissues with a black discoloration, which can be considered to be a main drawback specifically, when it is used on anterior teeth. nano-silver fluoride varnish preparation showed high efficacy in arresting caries progression in primary teeth without causing black discoloration to the tissues.silver diamine fluoride (sdf) . benefits for patient: 1. non-invasive treatment leading to reduce patient anxiety and stress. 2. no drilling and filling. 3. protects against further caries progression. benefits for the practitioner: 1. provide alternative treatment options. 2. pain-free procedure that facilitates child management and saves time. benefits for the community: 1. increasing overall oral health 2. provides more information by testing new material 3. to provide better service quality.

Eligibility criteria:
inclusion criteria: * children aged from 3 to 5 years * clinical diagnosis of active dentinal caries in primary teeth * co-operative participants and free of any systemic diseases exclusion criteria: * children whose parents refuse to sign consent * primary teeth with pulp involvement, pain, mobility, abscess, sinus, fistula; or discoloration related to tooth non-vitality.
vicriviroc (sch 417690) treatment protocol in human immunodeficiency virus (hiv)-infected participants: a rollover study for actg protocol a5211 (p04100)

Conditions: HIV; HIV Infections

Summary: the purpose of this study is to provide open-label vicriviroc (vcv) to human immunodeficiency virus (hiv) treatment-experienced participants who successfully completed 48 weeks of treatment on acquired immunodeficiency syndrome (aids) clinical trial group (actg) protocol a5211 (or who responded favorably to treatment but discontinued participation due to viral tropism shifts), and participants who screened for actg a5211 and met all inclusion/exclusion criteria, but were unable to enroll due to protocol closure.


Eligibility criteria:
inclusion criteria: * successful completion of actg protocol a5211, or favorable response in a5211 but discontinued due to tropism shift, or screened for a5211 and met inclusion/exclusion criteria but unable to enroll due to protocol closure. * participants must also be on a ritonavir-containing antiretroviral regimen at entry, and have acceptable hematologic and laboratory parameters. * female participants of reproductive potential must agree to use 2 reliable methods of contraception, including a barrier method, and must have a negative urine pregnancy test prior to dosing. exclusion criteria: * history of seizure or drug use that increases risk of seizure, current use of cyp3a4 inducers, prior history of malignancy, active drug or alcohol use or dependence that would interfere with study requirements * female participants who are breast-feeding, pregnant, or plan to become pregnant * participation in a clinical trial with another investigational drug. * participants with serious illness requiring systemic therapy and/or hospitalization must not begin vcv (if not already on vcv) until participant completes therapy or is clinically stable on therapy for at least 14 days prior to enrollment.

Keywords: treatment experienced
retrospective simplex high viscosity (hv) bone cement study

Conditions: Arthritis Knee; Aseptic Loosening

Summary: this study is a retrospective multicenter study to review the use of simplex high viscosity bone cement in primary total knee arthroplasty

this study is a retrospective investigation of subjects who have received primary triathlon total knee arthroplasty inserted with simplex high viscosity (hv) cement to evaluate the success rate defined as absence of revision for aseptic loosening of components at two years postoperative.

Eligibility criteria:
inclusion criteria: * the patient is age 18 or over at time of study device implantation * patients who have undergone primary triathlon total knee arthroplasty in which simplex hv/simplex hv gentamicin was indicated for fixation and used on label * patients who have been followed for at least 24 months postoperatively exclusion criteria: * patients who have undergone revision surgery * patients who have undergone bilateral knee arthroplasty * patients contraindicated for either the devices implanted, or the cement used, according to medical history review and instructions for use * patient has a cementless tibial baseplate. * patient has an active or suspected latent infection in or about the affected knee joint * patient has muscle loss or neuromuscular impairment in the affected limb that would create an unjustifiable risk * patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. \> 30 days) * patient has a known hypersensitivity to any of the cements constituents or in patients with severe renal failure * patient is a prisoner

Keywords: bone cement knee arthroplasty
an extension study of safety and tolerability of sep-363856 in adult subjects with schizophrenia

Conditions: Schizophrenia

Summary: an extension study of safety and tolerability of sep-363856 in adult subjects with schizophrenia

this is a 26 week, multiregional, open-label extension study designed to evaluate the long-term safety and tolerability of sep-363856 for the treatment of subjects with schizophrenia who have completed the 4 week double-blind treatment phase of study sep361-201 (nct02969382) subjects received open-label sep-363856 50 mg/day from day 1 through day 3, and then received flexible dosing of sep-363856 (25, 50, or 75 mg/day) for the rest of the trial. no statistical hypothesis tests will be performed.

Eligibility criteria:
inclusion criteria: subject must give written informed consent and privacy authorization prior to participation in the study and able to comply with the protocol, in the opinion of the investigator. * subject has completed study sep361 201 through week 4 * subject has not taken any medication other than the study drug for the purpose of controlling schizophrenia symptoms during study sep361 201. * female subject must have a negative urine pregnancy test at visit 7 of study sep361 201; females who are post-menopausal (defined as at least 12 months of spontaneous amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from the pregnancy test. * male subjects with female partner(s) of childbearing potential must agree to avoid fathering a child and use acceptable methods of birth control from screening until at least 30 days after the last study drug administration exclusion criteria: * subject answers "yes" to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the c-ssrs assessment at visit 7 of study sep361 201. subjects who answer "yes" to this question must be referred to the investigator for follow up evaluation. * subject has a clinically significant abnormality including physical examination, vital signs, ecg, or laboratory test at visit 7 of study sep361 201 that the investigator in consultation with the medical monitor considers to be inappropriate to allow participation in the study. * subject has a positive urine drug screen (uds) or breath alcohol test at visit 7 of study sep361 201. * subject is pregnant or lactating. * subject is at high risk of non-compliance in the investigator's opinion. * subject is in the opinion of the investigator, unsuitable in any other way to participate in this study.

Keywords: schizophrenia
a study of ccctc-binding factor (ctcf) in infantile hemangiomas

Conditions: Hemangioma

Summary: the purpose of this study is to evaluate the genotype of ctcf, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. the investigators aim to determine whether or not the ctcf genotype might serve as an early and reliable predictor of tumor growth.

this study seeks to examine a potential relationship between ctcf genotype and hemangioma size and growth rate. in addition to the initial visit, patients will return to our clinic for evaluation at two weeks, one month, two months, six months, and one year. at each visit, patients' hemangiomas will be measured and photographed. at one point over the course of evaluation, a blood sample will be taken from each patient for evaluation of c/t polymorphism at ctcf binding site six.

Eligibility criteria:
inclusion criteria: * hemangioma must appear within one month prior to enrollment exclusion criteria: * hemangioma appeared before one month prior to enrollment
preventing post-vaccination presyncope and syncope in adolescents using simple, clinic-based interventions: a pilot study

Conditions: Syncope, Vasovagal

Summary: this is a randomized controlled open-label trial. during the study, adolescents scheduled to receive at least one intramuscular (im) vaccine will receive either buzzy®, music, or buzzy® and music intervention(s) in addition to standard care to evaluate the feasibility and acceptability of these interventions prior to being used in a larger study to assess the effectiveness of the interventions in preventing post-vaccination presyncope and syncope. feasibility will be assessed according to study staff ability to successfully administer the protocol specified clinic-based interventions and per both study staff and healthcare provider responses to written feasibility assessments. acceptability will be assessed according to the participant's self-report. in addition, baseline needle phobia and anxiety, post-vaccination pain and presyncope symptoms, and pre- and post- vaccination state anxiety will be assessed per participant written self-report to standardized survey questions.


Eligibility criteria:
inclusion criteria: 1. 10 years through 17 years of age 2. if 10 through 13 years of age, the subject must be receiving at least one vaccine delivered intramuscularly 3. if 14 through 17 years of age, the subject must be receiving at least two injectable vaccines one of which must be delivered intramuscularly 4. the parent/guardian must be willing and capable of providing written informed consent for the adolescent and the adolescent must be willing and capable of providing assent. 5. the subject must be willing to stay for the completion of all study-related activities. 6. parent/guardian and adolescent must speak and read english by self-report exclusion criteria: 1. receipt of investigational or experimental vaccine or medication within the previous two weeks 2. receipt of routine injectable medication 3. permanent indwelling venous catheter 4. blood drawn within the past hour or scheduled for a blood draw during the post-vaccination observation period 5. injection of medication during the past hour or scheduled for injection of medication during the observation period. 6. cold intolerance or cold urticaria 7. raynaud's phenomenon 8. sickle cell disease 9. inability to hear 10. significant visual impairment or blindness 11. febrile or acutely ill individuals 12. upper arm or shoulder pain or injury 13. adolescent or parent/guardian is an immediate relative of study staff or an employee who is supervised by study staff. 14. any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol

Keywords: vaccination pre-syncope syncope prevention
accuracy of non-invasive blood pressure monitoring at the wrist in obese patients

Conditions: Obesity; Blood Pressure

Summary: arterial blood pressure (abp) monitoring is a corner stone in perioperative management. however, proper control of sbp requires accurate measurement of abp. the aim of this work is to validate the wrist obp monitor in obese patients and compare it to upper arm location (in accuracy, convenience, and trending) using invasive blood pressure monitor as a reference standard.

arterial blood pressure (abp) monitoring is a corner stone in perioperative management. recently, tight intraoperative individualized control of systolic blood pressure (sbp) (within 10% of baseline reading) was reported to reduce the risk of postoperative organ dysfunction in high risk patients undergoing abdominal procedures. however, proper control of sbp requires accurate measurement of abp. the gold standard for abp measurement is through a catheter placed in an artery. being an invasive, measurement of bp through an arterial catheter is restricted to patients with rapid major fluid shifts. many indirect methods are used for measurement of abp. oscillometric blood pressure (obp) monitoring is considered the standard non-invasive monitor for use in most clinical situations. in obp monitor, a pressure transducer located in the cuff senses the series of small oscillations heart-beat induced pulse volume changes. these oscillations are detected during deflation of the cuff pressure from above the sbp to diastolic blood pressure (dbp). the upper arm is the standard location of application of the blood pressure cuff as it is aligned with the heart level regardless the patient position. in obese patients, obp monitoring is considered superior to auscultatory method which is limited by faint auscultatory sounds. however, application of blood pressure cuff at the upper arm in this population is frequently limited by large arm circumference and asymmetrical arm contour. thus, locating the cuff at the wrist might be a more feasible alternative for the upper arm. obp monitoring at the wrist was previously compared to auscultatory measurement of abp in non-surgical patients. a recent study investigated the accuracy of obp at the upper forearm in obese patients. no data to the best of our knowledge validated obp monitoring at the lower forearm in obese patients using invasive blood pressure monitor as a reference standard. the aim of this work is to validate the wrist obp monitor in obese patients and compare it to upper arm location (in accuracy, convenience, and trending) using invasive blood pressure monitor as a reference standard.

Eligibility criteria:
inclusion criteria: * adult patients (aged above 18 years) * obese (with body mass index above 30 kg/squared meter) exclusion criteria: * peripheral vascular diseases * upper limb operations * upper limb scars * upper limb deep venous thrombosis * arrhythmias
study of disrupted sleep in somali americans

Conditions: Hypertension; Sleep Disorder; Healthy

Summary: the aims of this study are to determine the types and severity of previously undiagnosed sleep deficiencies in otherwise healthy somali americans, apply a research framework to define psychosocial, behavioral, environmental, and biological mechanisms mediating sleep deficiencies in somali americans, and examine the relationship between sleep deficiencies and increased blood pressure in somali americans.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with no known history of hypertension, diabetes, or sleep disorders. * self-identify as somali. * adult males and females who are older than 18 years of age. exclusion criteria: * anyone under 18 years or over 70 years. * positive pregnancy.
parpi and ovarian cancer survival

Conditions: Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum; PARP Inhibitor

Summary: with the widespread use of parp inhibitors (parpi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. this study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with parpi on survival rates in patients with advanced and recurrent ovarian cancer. the genetic status, different parpi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.


Eligibility criteria:
inclusion criteria: group 1: * patients newly diagnosed with stage iiic or iv primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between december 2013 and december 2024. * complete data on first-line treatment and maintenance therapy. * availability of follow-up data. group 2: * patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between december 2013 and december 2024. * disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen. * complete data on second-line treatment and maintenance therapy. * availability of follow-up data. exclusion criteria: group 1: * non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma. * missing first-line or follow-up data. group 2: * non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma. * patients with second relapse. * platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy. * missing second-line or follow-up data.
shear wave elastography for carotid atherosclerotic plaques

Conditions: Carotid Atherosclerosis

Summary: the goal of this prospective diagnostic accuracy cohort study is to compare the accuracy of carotid atherosclerotic plaques stiffness assessed by shear wave elastography (swe) with greyscale median values (gsm), magnetic resonance imaging (mri) and histopathological findings in patients with carotid atherosclerotic plaques causing stenosis above 50%, symptomatic or not. the main question it aims to answer is: is the plaque stiffness correlatable with gsm values, mri findings or histopathological findings? participants will be subjected to a vascular ultrasound study in which the swe and gsm will be assessed. the second imaging modality for stenosis confirmation will be mri and patients with confirmed symptomatic stenosis above 50% or assymptomatic stenosis above 70% will be considered for surgery intervention (endarterectomy or angioplasty). patients that undergo endarterectomy will have the carotid plaques subjected to a histopathological study. the study will not arbitrate about the treatment decision.


Eligibility criteria:
inclusion criteria: * patients with atherosclerotic carotid plaques that develop stenosis superior to 50%. exclusion criteria: * previous cervical surgery; * previous cervical radiotherapy; * stenosis caused by vascular inflammatory diseases; * pregnant women; * high carotid bifurcation (inaccessible by vascular ultrasound linear probe); * posterior acoustic shadowing that impair morphological evaluation of the plaque.
safety study of botulinum toxin type a for the treatment of focal upper limb poststroke spasticity

Conditions: Stroke; Muscle Spasticity

Summary: the purpose of this study is to evaluate the safety of repeated doses of botulinum toxin type a for the treatment of focal upper limb poststroke spasticity


Eligibility criteria:
inclusion criteria: * medically stable poststroke patients with spastic muscles in the upper limb exclusion criteria: * stroke within 6 months of study enrollment * previous therapy with botulinum toxin type a for treatment of any condition prior to 4 months of enrollment, for treatment of any condition prior to 01 january 1998